Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

[1]  E. Bruckert,et al.  Lowering LDL-cholesterol through diet: potential role in the statin era , 2011, Current opinion in lipidology.

[2]  V. Guarnotta,et al.  Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. , 2010, International angiology : a journal of the International Union of Angiology.

[3]  K. Kostner,et al.  Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia , 2010, Vascular health and risk management.

[4]  A. Goldberg.  Novel therapies and new targets of treatment for familial hypercholesterolemia. , 2010, Journal of clinical lipidology.

[5]  G. Vilahur,et al.  Nutraceuticals and atherosclerosis: human trials. , 2010, Cardiovascular therapeutics.

[6]  S. Yokoyama,et al.  Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. , 2010, Journal of atherosclerosis and thrombosis.

[7]  M. Eriksson,et al.  Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. , 2010, Clinical therapeutics.

[8]  M. McGowan,et al.  Nutritional supplements and serum lipids: Does anything work? , 2009, Current atherosclerosis reports.

[9]  T. Jacobson.  Myopathy with statin–fibrate combination therapy: clinical considerations , 2009, Nature Reviews Endocrinology.

[10]  Jonathan C. Cohen,et al.  PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. , 2009, Journal of Lipid Research.

[11]  E. Stein,et al.  Other therapies for reducing low-density lipoprotein cholesterol: medications in development. , 2009, Endocrinology and metabolism clinics of North America.

[12]  J. Geleijnse,et al.  Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. , 2009, The Journal of nutrition.

[13]  P. Kwiterovich.  Recognition and management of dyslipidemia in children and adolescents. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  A. Rees.  Familial hypercholesterolaemia: underdiagnosed and undertreated. , 2008, European heart journal.

[15]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[16]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[17]  Matthew K Ito,et al.  ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense? , 2007, The Annals of pharmacotherapy.

[18]  S. Ylä-Herttuala,et al.  Current status of cardiovascular gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  C. Keller.  Apheresis in Coronary Heart Disease With Elevated Lp (a): A Review of Lp (a) As a Risk Factor and Its Management , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[20]  S. Tonstad,et al.  Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. , 2006, Atherosclerosis.

[21]  P. Thompson,et al.  A systematic review of LDL apheresis in the treatment of cardiovascular disease. , 2006, Atherosclerosis.

[22]  M. Castro Cabezas,et al.  Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. , 2006, Journal of the American Dietetic Association.

[23]  P. Moriarty.  LDL-apheresis therapy , 2006, Current treatment options in cardiovascular medicine.

[24]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[25]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[26]  P. Thompson,et al.  An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.

[27]  E. Rahme,et al.  Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. , 2006, American heart journal.

[28]  A. Goldberg,et al.  Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. , 2006, The American journal of cardiology.

[29]  Sara Rosenbaum,et al.  Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. , 2005, The American journal of cardiology.

[30]  M. Zema.  Colesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients with Hypercholesterolemia , 2005, American journal of therapeutics.

[31]  R. Bambauer.  Is Lipoprotein (a)—Apheresis Useful? , 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[32]  K. Yamashita,et al.  Evaluation of Improved Coronary Flow Velocity Reserve Using Transthoracic Doppler Echocardiography After Single LDL Apheresis , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[33]  F. V. van Bockxmeer,et al.  Lipid disorders and mutations in the APOB gene. , 2004, Clinical chemistry.

[34]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[35]  I. Amano,et al.  Changes in Oxidative Stress and Microcirculation by Low‐density Lipoprotein Apheresis , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[36]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[37]  A. Schwarting,et al.  Differential Indication of Lipoprotein Apheresis During Pregnancy , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[38]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.

[39]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[40]  V. Armstrong,et al.  First Steps Toward the Establishment of a German Low‐Density Lipoprotein‐Apheresis Registry: Recommendations for the Indication and for Quality Management , 2002 .

[41]  G. Hansson.  Vaccination against atherosclerosis: science or fiction? , 2002, Circulation.

[42]  W. Hörl,et al.  Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. , 2002, Metabolism: clinical and experimental.

[43]  D. Gaudet,et al.  Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia , 2002, Circulation.

[44]  A. Lichtenstein,et al.  Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. , 2002, Journal of lipid research.

[45]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[46]  S. Grundy.  United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. , 2001, The American journal of cardiology.

[47]  J. Mckenney,et al.  Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia , 2001, Clinical cardiology.

[48]  D. Illingworth,et al.  Management of hypercholesterolemia. , 2001, The Medical clinics of North America.

[49]  C. White,et al.  Evaluation of the Antihyperlipidemic Properties of Dietary Supplements , 2001, Pharmacotherapy.

[50]  D. Rader,et al.  Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. , 2001, The American journal of cardiology.

[51]  M. V. van’t Hof,et al.  The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.

[52]  F. Dunne,et al.  Is normal pregnancy atherogenic? , 1999, Clinical science.

[53]  A. Goldberg.  Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. , 1998, The American journal of cardiology.

[54]  D. Capuzzi,et al.  A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. , 1998, The American journal of cardiology.

[55]  D. Capuzzi,et al.  Treatment of hyperlipidemia with combined niacin-statin regimens. , 1998, The American journal of cardiology.

[56]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia , 1998 .

[57]  B. Höfling,et al.  Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. , 1998, Metabolism: clinical and experimental.

[58]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[59]  A. Gotto,et al.  Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system , 1998 .

[60]  Clare,et al.  Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. , 1997, Journal of lipid research.

[61]  H. Davis,et al.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.

[62]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[63]  J. Reiber,et al.  LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. , 1996, Circulation.

[64]  R. Prescott,et al.  Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis , 1995, The Lancet.

[65]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[66]  W. Voelker,et al.  The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia , 1994, The clinical investigator.

[67]  T. Risler,et al.  Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. , 1994, Journal of lipid research.

[68]  A. Soutar,et al.  Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. , 1993, Atherosclerosis.

[69]  A. Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[70]  T. Nishide,et al.  Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. , 1992, Atherosclerosis.

[71]  V. Armstrong,et al.  The HELP‐LDL‐apheresis multicentre study, an angiographically assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease , 1991, European journal of clinical investigation.

[72]  P. Zimetbaum,et al.  Nicotinic Acid for the Treatment of Hyperlipoproteinemia , 1991, Journal of clinical pharmacology.

[73]  R. Touraine,et al.  [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. , 1967, Bulletins et memoires de la Societe medicale des hopitaux de Paris.

[74]  Megan E. Piper,et al.  Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. , 2011, American heart journal.

[75]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[76]  M. Nishimura,et al.  Improvement of endothelium‐dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia , 2004, Journal of clinical apheresis.

[77]  B. Rosner,et al.  Cholesterol-lowering effects of dietary fiber: a meta-analysis. , 1999, The American journal of clinical nutrition.

[78]  A. Thai,et al.  Lipid profiles during and after normal pregnancy. , 1991, Gynecologic and obstetric investigation.

[79]  Connor We,et al.  Dietary treatment of familial hypercholesterolemia. , 1989 .